



## Vigamox<sup>®</sup> (moxifloxacin) – First-time generic

- On July 3 – 5, 2017, generic versions of Alcon's [Vigamox \(moxifloxacin\)](#) 0.5% ophthalmic solution were launched.
  - [Apotex announced](#) the launch of an [AT-rated](#) version of Vigamox.
  - [Lupin announced](#) the launch of an [AT-rated](#) version Vigamox.
  - In addition, Watson received [FDA approval](#) of an [AT-rated](#) version of Vigamox. Launch plans are pending for this product.
- Vigamox is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.
  - Consult Vigamox's drug label for a listing of the specific organisms.
- Moxifloxacin 0.5% ophthalmic solution is also available as [Moxeza<sup>®</sup>](#).
  - Moxeza is also approved to treat bacterial conjunctivitis; however, there are differences in which organisms are covered vs. Vigamox.
- According to IMS, U.S. annual sales for Vigamox were approximately \$267.9 million for the 12 months ending in March 2017.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.